Innocrin Receives $28,000,000 Series D Funding Round

  • Feed Type
  • Date
    4/16/2015
  • Company Name
    Innocrin
  • Mailing Address
    4505 Emperor Boulevard Durham, NC 27703 USA
  • Company Description
    Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC).
  • Website
    http://www.innocrinpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $28,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Innocrin plans to use the proceeds to accelerate parallel Phase 2 CRPC program studies that are being led by the Memorial Sloan Kettering Cancer Center (MSK) and the NCI.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy